C
Connect Biopharmaceuticals
Biotech & Life Sciences · Suzhou Shi, China · Founded 2012
Connect Biopharmaceuticals, Ltd. is a clinical-stage company that discovers MoreLess
Connect Biopharma is a global clinical-stage biopharmaceutical company focused on creating innovative therapies for chronic inflammatory diseases driven by T cell biology. The company operates in key markets including China, the United States, Australia, and Europe, leveraging its expertise in functional cellular assays with T cells to discover and develop potent drug candidates. Connect Biopharma's business model revolves around the internal design and ownership of small molecules and antibodies, which are then advanced through clinical trials. Revenue is generated through the development and potential commercialization of these therapies, targeting conditions such as atopic dermatitis. The company serves patients suffering from chronic inflammatory diseases, aiming to improve their quality of life through cutting-edge medical research and development.
Keywords: T cell biology, chronic inflammatory diseases, biopharmaceutical, clinical-stage, small molecules, antibodies, atopic dermatitis, global operations, drug discovery, clinical trials.
Company overview
Connect Biopharmaceuticals company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2012
- Headquarters
- Suzhou Shi, China
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 61.0
Valuation & funding
Connect Biopharmaceuticals funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT VCOther financing | Mar 2026 | $0 | — | Panacea Venture | ↗ |
| IPOOther financing | Mar 2021 | $191M | $191M | Undisclosed | — |
| SERIES COther financing | Aug 2020 | $115M | $460M | Lilly Asia Ventures · Boxer Capital · Qiming Venture Partners · RA Capital Management | — |
| SERIES BOther financing | Jan 2019 | $55M | $220M | Qiming Venture Partners · Advantech Capital · NLVC · Cowin Capital | ↗ |
| SERIES AOther financing | Jan 2017 | $20M | $80M | NLVC · Cowin Capital · Qiming Venture Partners | — |
| SEEDOther financing | Nov 2016 | Cowin Capital | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $64K | 0% | −$57M | -89640.6% |
| 2025 | $64K | -99.8% | −$57M | -89640.6% |
| 2024 | $26M | — | −$22M | -83.7% |
| 2023 | $0 | — | −$61M | — |
| 2022 | $0 | — | −$105M | — |
| 2021 | $0 | — | −$179M | — |
| 2020 | $0 | — | −$106M | — |
Growth signals
Connect Biopharmaceuticals website traffic
Latest recorded traffic for Connect Biopharmaceuticals is 2.9K monthly website visits, down 85.5% over the last three months.
Comparisons
Connect Biopharmaceuticals compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Connect Biopharmaceuticals's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Connect Biopharmaceuticals's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Connect Biopharmaceuticals has talent and traffic
In the news
Latest news about Connect Biopharmaceuticals
Recent press, funding announcements, and product moves mentioning Connect Biopharmaceuticals — open to read from the original sources.
Market sentiment
What the market is saying about Connect Biopharmaceuticals
An AI-synthesized read of the highest-engagement posts about Connect Biopharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Connect Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.